Search Results - "Noviello, S"

Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C by Smith, A K, Simon, J S, Gustafson, E L, Noviello, S, Cubells, J F, Epstein, M P, Devlin, D J, Qiu, P, Albrecht, J K, Brass, C A, Sulkowski, M S, McHutchinson, J G, Miller, A H

“…Interferon (IFN)-α treatment for infectious diseases and cancer is associated with significant depressive symptoms that can limit therapeutic efficacy…”
Get full text

Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model by Huang, D. B., Noviello, S., Gemmell, C. G.

“…Staphylococcus aureus is the most common non-gonococcal aetiology of septic arthritis. The efficacy of iclaprim against S. aureus LS-1, a clinical strain…”
Get full text

BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study by Sanyal, A, Charles, E.D, Neuschwander-Tetri, B, Loomba, R, Harrison, S, Abdelmalek, M, Lawitz, E, Halegoua-DeMarzio, D, Dong, Y, Noviello, S, Krishnamoorthy, S, Luo, Y, Christian, R

Get full text

LP01 : Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: The ALLY-2 study by Wyles, D.L, Ruane, P, Sulkowski, M.S, Dieterich, D, Luetkemeyer, A.F, Morgan, T.R, Sherman, K.E, Liu, Z, Noviello, S, Ackerman, P

Get full text

LO8 : Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study by Poordad, F, Schiff, E.R, Vierling, J.M, Landis, C, Fontana, R.J, Yang, R, McPhee, F, Hughes, E, Noviello, S, Swenson, E.S

Get full text

P0866 : Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis C genotype 3: A matching-adjusted indirect comparison by Swallow, E, Song, J, Yuan, Y, Kalsekar, A, Kelley, C, Mu, F, Kim, S, Noviello, S, Signorovitch, J

Get full text

Factors Impacting SVR12 for Patients with Advanced Cirrhosis Receiving Daclatasvir and Sofosbuvir with Ribavirin in the Ally-1 Study by Poordad, F, Fontana, R, Schiff, E, Vierling, J.M, Landis, C, Zhao, Y, Gandhi, Y, Garimella, T, Eley, T, Noviello, S, Swenson, E.S

Get full text

Transient bacteraemia due to Chryseobacterium indologenes in an immunocompetent patient: a case report and literature review by Esposito, Silvano, Russo, E., De Simone, G., Gioia, R., Noviello, S., Vitolo, M., Rega, M. R., Massari, A., Posteraro, L.

“…A 51-year-old woman was admitted to the emergency unit with diffuse headache, visus reduction, and paraesthesias of the trigeminal area and the left hand…”
Get full text

Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison by Esposito, S., Noviello, S., Leone, S., Tice, A., Seibold, G., Nathwani, D., Scaglione, F.

“…In order to assess how outpatient parenteral antibiotic therapy (OPAT) is managed in different countries, we analyzed the data collected in the USA, UK and…”
Get full text

P0782 : All-oral 12-week combination treatment with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-experienced patients infected with HCV genotype (GT) 3: A subanalysis of the ALLY-3 phase 3 study by Nelson, D, Bernstein, D, Freilich, B, Lawitz, E, Hawkins, T, Pockros, P, Thuluvath, P, Younes, Z, Bennett, M, Ghalib, R, Ruane, P.J, Tong, M, Bhore, R, Yin, P.D, Noviello, S, Rana, K

Get full text

P0829 : On-treatment HCVRNA as a predictor of sustained virologic response in HCV genotype 3 infected patients treated with daclatasvir and sofosbuvir: analysis of phase 3 ALLY-3 study by Kowdley, K, Nelson, D, Lalezari, J, Box, T, Gitlin, N, Poleynard, G, Rabinovitz, M, Ravendhran, N, Sheikh, A, Siddique, A, Bhore, R, Yin, P.D, Noviello, S, Rana, K

Get full text

Hepatitis C treatment among racial and ethnic groups in the IDEAL trial by Muir, A. J., Hu, K. -Q., Gordon, S. C., Koury, K., Boparai, N., Noviello, S., Albrecht, J. K., Sulkowski, M. S., McCone, J.

“…Previous studies of chronic hepatitis C virus (HCV) treatment have demonstrated variations in response among racial and ethnic groups including poorer efficacy…”
Get full text

Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response by Clark, P. J., Thompson, A. J., Zhu, M., Vock, D. M., Zhu, Q., Ge, D., Patel, K., Harrison, S. A., Urban, T. J., Naggie, S., Fellay, J., Tillmann, H. L., Shianna, K., Noviello, S., Pedicone, L. D., Esteban, R., Kwo, P., Sulkowski, M. S., Afdhal, N., Albrecht, J. K., Goldstein, D. B., McHutchison, J. G., Muir, A. J.

“…Low‐density lipoprotein cholesterol (LDL‐C) levels and interleukin 28B (IL28B) polymorphism are associated with sustained viral response (SVR) to…”
Get full text

P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY by Kao, J.-H, Heo, J, Yoffe, B, Sievert, W, Jacobson, I, Bessone, F, Peng, C.-Y, Roberts, S, Yoon, K.T, Kopit, J, Linaberry, M, Noviello, S, Hughes, E, Manns, M

Get full text

Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C by Xu, C., Gupta, S., Krishna, G., Cutler, D., Wirth, S., Galoppo, C., Ciocca, M., Kolz, K., Noviello, S., Sniukiene, V.

“…Purpose The aim of this study was to characterize the population pharmacokinetics of peginterferon (PEG-IFN) alfa-2b in pediatric patients with chronic…”
Get full text

O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS by Manns, M, Pol, S, Jacobson, I, Marcellin, P, Gordon, S, Peng, C.-Y, Chang, T.-T, Everson, G, Heo, J, Gerken, G, Yoffe, B, Towner, W.J, Bourliere, M, Metivier, S, Chu, C.-J, Sievert, W, Bronowicki, J.-P, Thabut, D, Lee, Y.-J, Kao, J.-H, McPhee, F, Kopit, J, Mendez, P, Linaberry, M, Hughes, E, Noviello, S

Get full text

Foot infections in diabetes (DFIs) in the out-patient setting: an Italian multicentre observational survey by Esposito, S., Leone, S., Noviello, S., Fiore, M., Ianniello, F., Felaco, F. M., Romagnoli, F., Sarli, E.

“…Aims  To conduct a multicentre observational study to describe management of foot infections in diabetes in the out‐patient setting in Italy. Patients and…”
Get full text

1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY by Dore, G.J, Lawitz, E, H'ezode, C, Shafran, S, Ramji, A, Tatum, H, Taliani, G, Tran, A, Brunetto, M, Zaltron, S, Strasser, S, Weis, N, Ghesquiere, W, Lee, S, Larrey, D, Pol, S, Harley, H, George, J, Fung, S, de L'edinghen, V, Hagens, P, Cohen, D, Cooney, E, Noviello, S, Hughes, E

Get full text

Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin by Kelly, D. A., Haber, B., González-Peralta, R. P., Murray, K. F., Jonas, M. M., Molleston, J. P., Narkewicz, M. R., Sinatra, F. R., Lang, T., Lachaux, A., Wirth, S., Shelton, M., Te, H. S., Pollack, H., Deng, W., Noviello, S., Albrecht, J. K.

“…Long‐term studies in adults indicate that sustained virologic response (SVR) after combination treatment for chronic hepatitis C (CHC) predicts long‐term…”
Get full text

Comparative activity of garenoxacin and other agents by susceptibility and time–kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens by Noviello, Silvana, Ianniello, Filomena, Leone, Sebastiano, Esposito, Silvano

“…Objectives: Garenoxacin is a novel des-F(6)quinolone that has shown excellent antimicrobial activity against a wide range of clinically important…”
Get full text